Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMENO-2: Phase IV Study, National, Multiple Center, Comparative, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Safety, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors.

Next Previous
Trial Profile

AMENO-2: Phase IV Study, National, Multiple Center, Comparative, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Safety, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Palonosetron (Primary) ; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms AMENO-2

Most Recent Events

  • 12 Jun 2011 Results presented at the 16th Congress of the European Hematology Association.
  • 08 Jun 2011 Results were presented at the Annual Meeting of the European Haematological Association (EHA-2011).
  • 22 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top